Was Duncan McKechnie’s Vertex (VRTX) share sale made under a Rule 10b5-1 plan?

Yes, the sale was executed under a company-approved Rule 10b5-1 trading plan. The footnote states the plan was entered into on November 25, 2025, indicating the trade’s timing was pre-arranged rather than a discretionary market-timing decision.

Vertex EVP sells 1,541 shares at $519

Vertex Pharmaceuticals executive Duncan McKechnie, EVP and Chief Commercial Officer, sold 1,541 shares of Common Stock in an open-market transaction at $519.00 per share on July 2, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Duncan McKechnie, EVP and Chief Commercial Officer, sold 1,541 shares of Common Stock in an open-market transaction at $519.00 per share on July 2, 2026. Following this sale, he directly holds 11,001 shares. The transaction was made under a company-approved trading plan pursuant to Rule 10b5-1 entered into on November 25, 2025, indicating it was pre-scheduled rather than discretionary.

Insider Trade Summary 10b5-1

Net Seller: 1,541 shares

Net Sell 1 txn

Insider McKechnie Duncan

Role EVP, Chief Commercial Officer

Sold 1,541 shs ($800K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,541	$519.00	$800K

Holdings After Transaction: Common Stock — 11,001 shares (Direct)

Footnotes (1)

F1. Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

Key Figures

Shares sold: 1,541 shares Sale price: $519.00 per share Shares held after sale: 11,001 shares

3 metrics

Shares sold 1,541 shares Common Stock sold on July 2, 2026

Sale price $519.00 per share Open-market transaction

Shares held after sale 11,001 shares Direct ownership after transaction

Key Terms

Rule 10b5-1, open-market sale, Common Stock

3 terms

Rule 10b5-1 regulatory

"company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vertex (VRTX) report for Duncan McKechnie?

Vertex reported that EVP and Chief Commercial Officer Duncan McKechnie sold 1,541 shares of Common Stock. The open-market sale occurred on July 2, 2026 at $519.00 per share under a pre-established Rule 10b5-1 trading plan.

How many Vertex (VRTX) shares did Duncan McKechnie sell and at what price?

Duncan McKechnie sold 1,541 Vertex Common Stock shares at $519.00 per share. This was an open-market transaction executed on July 2, 2026 as part of his company-approved Rule 10b5-1 trading plan.

How many Vertex (VRTX) shares does Duncan McKechnie hold after this sale?

After the July 2, 2026 sale, Duncan McKechnie directly holds 11,001 shares of Vertex Common Stock. This figure reflects his position immediately following the 1,541-share open-market transaction disclosed in the Form 4 filing.

What role does Duncan McKechnie hold at Vertex (VRTX) in this Form 4 filing?

In this Form 4, Duncan McKechnie is identified as Executive Vice President and Chief Commercial Officer. His reported transaction involves a direct, open-market sale of Vertex Common Stock under a pre-established Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/07/2026 - 04:08 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKechnie Duncan

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/02/2026		S⁽¹⁾		1,541	D	$519	11,001	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR